Germany’s Expert Committee for Prescription remained unmoved by the evidence and arguments presented by an unnamed applicant in favor of a third Rx-to-OTC switch application for sildenafil.
In fact, German medicines agency BfArM in its presentation to the committee said it saw nothing new in the application,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?